Drug Search Results
More Filters [+]

Biolimus

Alternative Names: biolimus
Latest Update: 2024-05-07
Latest Update Note: PubMed Publication

Product Description

The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01137019)

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Colombia | United Arab Emirates

Approved Indications: None

Known Adverse Events: None

Company: Biosensors Europe
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Biolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Coronary Artery Disease|Myocardial Ischemia|Dyslipidemia|Hypertension|Angina, Stable|ST Elevation Myocardial Infarction|Acute Coronary Syndrome|Myocardial Infarction|Thrombosis|Inflammation|Stroke

Phase 3: Coronary Artery Disease|Myocardial Ischemia|Coronary Disease

Phase 2: Coronary Thrombosis|Coronary Artery Disease|Myocardial Ischemia|ST Elevation Myocardial Infarction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2000041438

N/A

Recruiting

Coronary Disease

2025-12-31

JW-PM-DCB-2024

N/A

Not yet recruiting

Coronary Artery Disease|Myocardial Ischemia

2025-12-30

REFORM

N/A

Unknown status

Coronary Restenosis|Coronary Artery Disease|Coronary Stenosis

2023-04-01

SORTOUTXI

N/A

Active, not recruiting

Coronary Artery Disease

2023-03-19

Recent News Events